Skip to content

Opko Health OPK Royalty — Revenue

Other product segments

Intellectual Property And Other
$46.1M
Transfer Of Intellectual Property And Other
$46.09M+208%
Rayaldee
$14.26M

Similar metrics at other companies

Mannkind logo
MNKDRoyalty — Revenue
$32.75M+9.1%
PTC Therapeutics logo
PTCTRoyalty — Revenue
$46.84M+28.5%
EyePoint, Inc.
 logo
EYPTRoyalty — Revenue
$141K-98.9%
Ultragenyx Pharmaceutical logo
RARERoyalty — Revenue
$47M-2.1%
Dianthus Therapeutics logo
DNTHRoyalty — Revenue
$0
Byrna Technologies, Inc. logo
BYRNRoyalty — Revenue
-$282K-135%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$921.21M-14.0%
P/S1.6×0.0×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Opko Health’s 10-Q, filed July 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's royalty — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's royalty — revenue?
Opko Health (OPK) reported royalty — revenue of $6.4M in Q2 2026.
What does royalty — revenue mean?
This metric measures the gross revenue recognized from licensing intellectual property or technology assets, excluding any pass-through sales or value-added taxes. It serves as a primary indicator of the commercial success and market adoption of the company's proprietary developments. Monitoring this figure helps stakeholders evaluate the underlying performance of the royalty-generating segment independent of tax-related fluctuations.